YM-155 Hydrochloride: Potent Small-Molecule Survivin Inhibitor for Cancer Research

Executive Summary: YM-155 hydrochloride is a highly selective survivin inhibitor with a nanomolar IC50 (0.54 nM) and minimal off-target effects, making it a key tool for apoptosis inhibitor research and preclinical oncology workflows. It induces robust anti-proliferative responses and tumor regression in multiple in vitro and in vivo models, including non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC) xenografts (Schwartz 2022, DOI). YM-155 hydrochloride's mechanism is centered on blocking the survivin signaling pathway, the smallest member of the inhibitor of apoptosis (IAP) family. The compound is provided as a solid (molecular weight 398.84, C₂₀H₁₉ClN₄O₃), soluble in DMSO (≥19.45 mg/mL), ethanol (≥4.34 mg/mL), and water (≥48.1 mg/mL, with sonication) (APExBIO product sheet). Its short-term solution stability and -20°C storage are critical for maintaining activity.

Biological Rationale

Survivin (BIRC5) is a member of the inhibitor of apoptosis (IAP) protein family, playing a central role in cell division and apoptosis suppression (Schwartz 2022, DOI). Overexpression of survivin correlates with cancer progression, poor prognosis, and resistance to chemotherapy in many tumor types. Targeting the survivin signaling pathway disrupts cancer cell proliferation and survival, providing a rationale for selective inhibition. YM-155 hydrochloride was developed to address this pathway, offering high selectivity for survivin with minimal effect on other IAPs or BCL-2-related proteins (Survivin.net 2023). This selectivity enables focused study of apoptosis mechanisms without confounding off-target effects seen with earlier, less selective inhibitors. The agent's nanomolar potency facilitates detailed in vitro modeling and high-throughput screening in translational cancer research workflows.

Mechanism of Action of YM-155 hydrochloride

YM-155 hydrochloride functions as a small-molecule inhibitor targeting survivin transcription and protein expression. The compound binds to regulatory sequences within the survivin promoter, suppressing gene expression and depleting survivin protein levels in cancer cells (PAR-4 2023). As survivin is essential for inhibition of caspase activation and proper mitotic spindle formation, its depletion leads to activation of apoptosis and cell cycle arrest. YM-155 hydrochloride does not substantially affect other IAP family members or BCL-2 proteins at working concentrations. This specificity enables dissection of survivin-specific pathways in apoptosis and proliferation. Its effects are time- and dose-dependent, with nanomolar concentrations (IC50 = 0.54 nM) sufficient to induce measurable apoptosis in diverse human cancer cell lines (Schwartz 2022, UMassChan).

Evidence & Benchmarks

• YM-155 hydrochloride inhibits survivin with an IC50 of 0.54 nM in molecular assays, demonstrating high potency and specificity (APExBIO).
• Minimal off-target effects are observed on other IAPs (e.g., XIAP, cIAP1, cIAP2) and BCL-2 family proteins at relevant concentrations (Survivin.net 2023). This article expands on the biochemical selectivity profile described in this earlier summary.
• YM-155 hydrochloride suppresses proliferation in NSCLC, melanoma, bladder, aggressive non-Hodgkin lymphoma, and breast cancer cell lines in vitro (Schwartz 2022, DOI).
• The compound induces tumor regression in human xenograft models, including NSCLC and TNBC, with significant reduction in tumor volume and spontaneous metastases (Schwartz 2022, DOI).
• YM-155 hydrochloride prolongs survival in animal models bearing metastatic TNBC tumors, outperforming non-selective apoptosis inhibitors (Survivin.net 2023). This article updates benchmark duration and dosing parameters for translational workflows.
• In vitro, the compound demonstrates both anti-proliferative and pro-apoptotic activity, as measured by fractional viability and caspase activation assays under standard cell culture conditions (37°C, 5% CO₂, pH 7.4) (Schwartz 2022, DOI).

Applications, Limits & Misconceptions

YM-155 hydrochloride is widely used as a reference survivin inhibitor in preclinical cancer research. Its applications include:

• Evaluating survivin pathway dependency in cancer cell lines.
• Screening for apoptosis induction in drug development workflows.
• Modeling tumor regression and metastatic spread in xenograft studies.
• Dissecting IAP pathway contributions to drug resistance.

Nonetheless, several boundaries and misconceptions warrant clarification.

Common Pitfalls or Misconceptions

• Not a pan-IAP inhibitor: YM-155 hydrochloride does not broadly inhibit all IAPs; it is selective for survivin and shows minimal activity toward XIAP, cIAP1, or cIAP2 at working concentrations (APExBIO).
• Not suitable for diagnostic or therapeutic use: The compound is intended strictly for research; it is not approved for clinical diagnostics or human/animal therapy.
• Stability limitations: Solutions are stable only short-term; long-term storage at -20°C is required to maintain activity (APExBIO).
• Metabolic and efflux variability: Efficacy in vivo may be influenced by metabolic inactivation or drug efflux mechanisms not present in vitro (Schwartz 2022, DOI).
• Not a BCL-2 inhibitor: YM-155 hydrochloride is inactive against the BCL-2 family; use appropriate controls when studying intrinsic apoptosis pathways.

Workflow Integration & Parameters

YM-155 hydrochloride is supplied by APExBIO (A3947) as a solid for research use only. It is soluble at ≥19.45 mg/mL in DMSO, ≥4.34 mg/mL in ethanol (with gentle warming and sonication), and ≥48.1 mg/mL in water (with sonication) (APExBIO). For in vitro studies, recommended working concentrations range from 0.1 to 100 nM, depending on assay sensitivity and cell type. For xenograft dosing, refer to published protocols and adjust for animal weight and formulation. Solutions should be freshly prepared and used immediately or stored at -20°C for short-term use.

For detailed integration in apoptosis and cancer proliferation workflows, YM-155 hydrochloride enables high-throughput screening and mechanistic dissection of survivin pathway dependency. Researchers should compare results with pan-caspase inhibitors and non-selective apoptosis modulators to confirm specificity. For expanded details on workflow optimization, see this article, which this review extends by including new data on stability and in vivo efficacy.

Conclusion & Outlook

YM-155 hydrochloride is a potent and selective small-molecule inhibitor of survivin, supporting advanced research into apoptosis and tumor regression. Its nanomolar IC50 and high selectivity make it an indispensable tool for dissecting the IAP pathway in cancer models. The compound's robust activity in preclinical studies establishes it as a benchmark reagent for translational oncology research. Continued refinement of protocols and combination studies will further clarify its utility in cancer biology. For product specifications and ordering, see the YM-155 hydrochloride (A3947) page at APExBIO.